Literature DB >> 25457019

Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.

Mark N Stein1, Kim M Hirshfield2, Hua Zhong3, Eric A Singer4, Siraj M Ali5, Shridar Ganesan2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25457019      PMCID： PMC5500309          DOI： 10.1016/j.eururo.2014.10.012

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  9 in total

1.  Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.

Authors:  Alex A Adjei; Brian Schwartz; Edward Garmey
Journal:  Oncologist       Date:  2011-05-31

2.  Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--response.

Authors:  Paolo Michieli; Cristina Basilico; Selma Pennacchietti
Journal:  Clin Cancer Res       Date:  2013-06-13       Impact factor: 12.531

3.  Targeted therapies: Tivantinib--a cytotoxic drug in MET inhibitor's clothes?

Authors:  Paolo Michieli; Federica Di Nicolantonio
Journal:  Nat Rev Clin Oncol       Date:  2013-05-28       Impact factor: 66.675

4.  Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.

Authors:  Yitzhak Zimmer; Angelina V Vaseva; Michaela Medová; Bruno Streit; Wieslawa Blank-Liss; Richard H Greiner; Nikolaus Schiering; Daniel M Aebersold
Journal:  Cancer Lett       Date:  2009-09-23       Impact factor: 8.679

5.  ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

Authors:  Neru Munshi; Sébastien Jeay; Youzhi Li; Chang-Rung Chen; Dennis S France; Mark A Ashwell; Jason Hill; Magdi M Moussa; David S Leggett; Chiang J Li
Journal:  Mol Cancer Ther       Date:  2010-05-18       Impact factor: 6.261

6.  Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

Authors:  L Schmidt; K Junker; N Nakaigawa; T Kinjerski; G Weirich; M Miller; I Lubensky; H P Neumann; H Brauch; J Decker; C Vocke; J A Brown; R Jenkins; S Richard; U Bergerheim; B Gerrard; M Dean; W M Linehan; B Zbar
Journal:  Oncogene       Date:  1999-04-08       Impact factor: 9.867

7.  Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.

Authors:  Timothy A Yap; David Olmos; Andre T Brunetto; Nina Tunariu; Jorge Barriuso; Ruth Riisnaes; Lorna Pope; Jeremy Clark; Andrew Futreal; Michael Germuska; David Collins; Nandita M deSouza; Martin O Leach; Ronald E Savage; Carol Waghorne; Feng Chai; Edward Garmey; Brian Schwartz; Stan B Kaye; Johann S de Bono
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

8.  Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.

Authors:  Cristina Basilico; Selma Pennacchietti; Elisa Vigna; Cristina Chiriaco; Sabrina Arena; Alberto Bardelli; Donatella Valdembri; Guido Serini; Paolo Michieli
Journal:  Clin Cancer Res       Date:  2013-03-26       Impact factor: 12.531

9.  Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.

Authors:  Ryohei Katayama; Aki Aoyama; Takao Yamori; Jie Qi; Tomoko Oh-hara; Youngchul Song; Jeffrey A Engelman; Naoya Fujita
Journal:  Cancer Res       Date:  2013-04-18       Impact factor: 12.701
  9 in total
  5 in total

Review 1.  Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact.

Authors:  Brandon J Manley; Abraham Ari Hakimi
Journal:  Curr Opin Urol       Date:  2016-09       Impact factor: 2.309

Review 2.  [Research Progress of Targeted Therapy for Anaplastic Lymphoma Kinase and Other Rare Driver Genes in Advanced Non-small Cell Lung Cancer].

Authors:  Quan Zhang; Shucai Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-01-20

Review 3.  Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review.

Authors:  Philippe Rochigneux; Jeanne Thomassin-Piana; Sophy Laibe; Serge Brunelle; Naji Salem; Bernard Escudier; Gilles Vassal; Gwenaelle Gravis
Journal:  BMC Cancer       Date:  2018-11-22       Impact factor: 4.430

4.  Tivantinib Hampers the Proliferation of Glioblastoma Cells via PI3K/Akt/Mammalian Target of Rapamycin (mTOR) Signaling.

Authors:  Yukun Wu; Zhizhang Li; Lijuan Zhang; Guiyang Liu
Journal:  Med Sci Monit       Date:  2019-10-02

5.  Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.

Authors:  Kim M Hirshfield; Denis Tolkunov; Hua Zhong; Siraj M Ali; Mark N Stein; Susan Murphy; Hetal Vig; Alexei Vazquez; John Glod; Rebecca A Moss; Vladimir Belyi; Chang S Chan; Suzie Chen; Lauri Goodell; David Foran; Roman Yelensky; Norma A Palma; James X Sun; Vincent A Miller; Philip J Stephens; Jeffrey S Ross; Howard Kaufman; Elizabeth Poplin; Janice Mehnert; Antoinette R Tan; Joseph R Bertino; Joseph Aisner; Robert S DiPaola; Lorna Rodriguez-Rodriguez; Shridar Ganesan
Journal:  Oncologist       Date:  2016-08-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.